Percheron Therapeutics Ltd - Company Profile
Powered by 
All the data and insights you need on Percheron Therapeutics Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Percheron Therapeutics Ltd Strategy Report
- Understand Percheron Therapeutics Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Percheron Therapeutics Ltd (Percheron Therapeutics) formerly Antisense Therapeutics Ltd, is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of second-generation antisense pharmaceuticals. The company focuses on the development of antisense drugs in the areas of immunology disorders and rare diseases such as multiple sclerosis (MS) among others. Percheron Therapeutics’ development pipeline comprises ATL1103 for a potential treatment for growth hormone disorders such as Acromegaly; ATL1102 (injection), which reduces brain lesions is being developed for the treatment of multiple sclerosis. ATL1102 is also being developed for the treatment of duchenne muscular dystrophy (DMD). Percheron Therapeutics is headquartered in Toorak, Victoria, Australia.
Headquarters
Australia
Address
14 Wallace Avenue, Toorak, Melbourne, Victoria, 3142
Website
www.antisense.com.au
Telephone
61 3 98278999
No of Employees
8
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PER (ASX)
Revenue (2022)
$267,000
1026.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-95.8%
(2022 vs 2021)
Market Cap*
$37.5M
Net Profit Margin (2022)
XYZ
82.6%
(2022 vs 2021)
* As of and is in US$
Percheron Therapeutics Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| ATL1103- Acromegaly |
| ATL1102 - Multiple Sclerosis, Duchenne Muscular Dystrophy (DMD) |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Corporate Changes/Expansions | In January, the company changed its name to Percheron Therapeutics Ltd. |
| 2023 | Regulatory Approval | In June, the company secured regulatory authority and ethics committee approval to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD) in the UK. |
| 2023 | Regulatory Approval | In February, the company secured regulatory authority approval from the Turkish Medicines and Medical Device Agency (TMMDA) to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne Muscular Dystrophy. |
Competitor Comparison
| Key Parameters | Percheron Therapeutics Ltd | Clinuvel Pharmaceuticals Ltd | Syntara Ltd | Genetic Technologies Ltd | Biosensis Pty Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | Australia | Australia |
| City | Melbourne | Melbourne | Frenchs Forest | Melbourne | Thebarton |
| State/Province | Victoria | Victoria | New South Wales | Victoria | South Australia |
| No. of Employees | 8 | 16 | 107 | 60 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James Garner | Chief Executive Officer; Managing Director; Director | Executive Board | 2023 | - |
| Phillip Hains | Secretary; Chief Financial Officer | Senior Management | 2006 | - |
| Anthony Filippis | Chief Operating Officer | Senior Management | 2022 | - |
| Charmaine Gittleson | Chairman | Non Executive Board | 2021 | - |
| Andrew McKenzie | Director - Clinical Development | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer